Enterprise Value
83.06M
Cash
29.67M
Avg Qtr Burn
-6.233M
Short % of Float
0.25%
Insider Ownership
1.34%
Institutional Own.
1.47%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pelareorep + Bavencio®(avelumab) Details Breast cancer | Phase 2 Data readout | |
Pelareorep + Retifanlimab Details Breast cancer, Triple-negative breast cancer | Phase 2 Update | |
Pelareorep + Atezolizumab (Tecentriq) Details Gastric cancer, Colorectal cancer , Cancer, Pancreatic cancer | Phase 1/2 Update | |
Pelareorep + Keytruda® Details Pancreatic cancer, Sarcoma | Failed Discontinued |